NCT03364738View on ClinicalTrials.gov

Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism

PHASE3TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

April 14, 2020

Study Completion Date

April 14, 2020

Conditions
Hypoparathyroidism
Interventions
BIOLOGICAL

rhPTH(1-84)

Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.

Trial Locations (10)

1083

Semmelweis Egyetem, Budapest

7624

Pecsi Tudomanyegyetem, I. sz. Belgyogyaszati Klinika, Pécs

8200

Aarhus Universitetshospital, Aarhus N

40536

University of Kentucky Medical Center, Lexington

43210

Ohio State University, Columbus

70006

Crescent City Clinical Research Center, LLC, Metairie

89511-2060

Northern Nevada Endocrinology - Lisa Abbott MD, Reno

19107-6810

Thomas Jefferson University, Jefferson Rheumatology Associates, Philadelphia

L6M 1M1

Bone Research and Education Centre, Oakville

G1V 4G2

CHU de Quebec-Universite Laval, Québec

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT03364738 - Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism | Biotech Hunter | Biotech Hunter